新天药业分析师会议 调研日期：2025年08月26日 调研行业：中药 参与调研的机构：摩根士丹利基金、财通基金、湘禾投资、东方 证券自营、国海富兰克林基金等 / 机构调研pro小程序 DJvanbao.com 洞见研报 出品 : 机构调研pro小程序致力于为金融证券投资者提供最新最全的调研会议纪要。 来机构调研pro小程序，了解最新的：行业投资风向、热门公司关注、权威机构分析... 权威完善的信息持续更新! 更多精彩的机构调报告请移步机构调研pro小程序~ 一解投资机构行业关注度。 频判市场 | Gallia | | | --- | --- | | 11 2 12 200 2 110 | | | 1:给我们 = 影片面临官 = | | | 阿里巴巴佩尼 | | | 钢铁机之题。 8 | 图纸制图: 23 | | 20GB Millio Aller 19 | | | 海双集团 | | | 1 1 80.0 0 | 总机构建 23 | | LOGA: REGH, KETA: 1986 | | | 小麦具日 | | | 的研究次数:8 | 上机构馆:23 | | 定年代的:用者点击:我要的中:主要原因 | | | ...

证券代码：002873 证券简称：新天药业 贵阳新天药业股份有限公司投资者关系活动记录表 编号：2025-003 | | □√特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 □√其他（线上会议、电话会议） | | 参与单位名称 | 摩根士丹利基金 财通基金 湘禾投资 东方证券自营 | | 及人员姓名 | 国海富兰克林基金 睿亿投资 华安证券 摩根基金 | | | 中欧基金 中邮证券 | | 时间 | 2025 年 8 月 26 日 | | 地点 | 上海市徐汇区东安路 562 号 22 层公司会议室、上海中心大厦 | | 上市公司接待 | 董事、副总经理、董事会秘书：王光平 | | 人员姓名 | 证券经理：梁永松 | | | 问题一、公司目前在研管线有哪些？相应的创新药研发进展如何？ | | | 答：近年来，公司除原有三个 1.1 类临床三期在研品种继续推进研发工作 | | | 外，还在其他重要治疗领域取得了一定的突破性进展，具体涵盖： | | | 个 类改良型新药），持续深化现有 ...

Core Viewpoint - The company Guizhou Xintian Pharmaceutical (002873.SZ) is embroiled in a bribery scandal involving its Chengdu branch, which allegedly engaged in bribing over 100 doctors across 37 medical institutions in Sichuan province, raising investor concerns [1][2]. Group 1: Allegations of Bribery and Misconduct - The Chengdu branch of Xintian Pharmaceutical is accused of collecting false case studies, conducting fake educational projects, hosting illegal banquets and entertainment activities, and improperly conducting departmental meetings to facilitate "profit transfer" [3]. - Allegations include the distribution of benefits to doctors through a survey project via the Sunflower Alliance App, involving 55 doctors from 15 hospitals, with an estimated total of approximately 72,600 yuan [3]. - The company reportedly organized 19 events in the first four months of 2025, involving 41 hospitals, where doctors were entertained and encouraged to prescribe the company's products [3]. Group 2: Financial Performance - Xintian Pharmaceutical has experienced a decline in performance over the past two years, with revenue dropping from a peak of 1.088 billion yuan in 2022 to 954 million yuan in 2023 and further to 858 million yuan in 2024 [7]. - The net profit also decreased from 110 million yuan in 2022 to 80.87 million yuan in 2023 and 52.32 million yuan in 2024, indicating a continuous shrinkage in earnings [7]. - The company's core product structure is heavily reliant on gynecological products, which accounted for 71.54% of revenue, but these products have seen a revenue decline of 9.21% in 2024 [7]. Group 3: Sales and Marketing Expenses - Sales expenses for Xintian Pharmaceutical remained high, with figures of 532 million yuan in 2022, 438 million yuan in 2023, and 372 million yuan in 2024, reflecting a sales expense ratio of 48.93%, 45.86%, and 43.34% respectively [8]. - In 2024, the company reported significant increases in meeting expenses, which rose to over 11 million yuan, compared to just 2.77 million yuan in the previous year [8]. Group 4: Acquisition and Ownership Issues - The company's planned acquisition of Shanghai Huilun Pharmaceutical, which would have made it a wholly-owned subsidiary, was terminated in July 2022, raising concerns about potential conflicts of interest as the controlling shareholder is linked to Huilun [11]. - The failed acquisition was seen as a missed opportunity for growth, with Huilun valued at 2.574 billion yuan at the time [11]. Group 5: Shareholder Actions - The controlling shareholder, Xintian Zhiyuan, plans to reduce holdings by up to 5.7 million shares, representing 2.42% of the total share capital, citing personal financial needs [12].

新京报贝壳财经讯（记者丁爽）5月28日，针对网传"贵阳新天药业股份有限公司成都分公司被举报贿赂 多位医生"一事，新京报贝壳财经记者拨通新天药业证代公开电话，工作人员对记者表示，"相关事项公 司已经知悉了，已经关注到了，暂时不便接受采访。" 5月28日收盘，新天药业股价报8.88元，跌2.09%。 此前一天，一封《关于贵阳新天药业股份有限公司向医生输送商业贿赂的举报信》以及一份由四川省卫 生健康委员会出具的核查通知在网络流传。核查通知提及，近期接到举报信，反映"部分医疗机构医生 涉嫌收受商业贿赂"等线索，要求相关单位协助核查，对发现违反卫生健康法律法规的行为依法查处。 不过，公司销售费用呈现逐年下降趋势。其在2024年年报中表示，自2022年开始，公司对市场营销体系 进行了改革与调整，结合市场需求和公司战略重点，对架构调整与团队建设、产品经理系统化培训、产 品与市场策略、品牌推广培训、市场协同、员工绩效考核机制等方面进行一定的改革。 公司称，本次营销体系改革主要基于进一步推进规模效应下的市场营销体系"降本增效"，加强营销团队 及产品营销推广的专业化、精细化管理等相关市场策略部署。同时，从结果来看，现阶段销售费用 ...